Lisa N. Silverman, Ph.D.

Lisa N. Silverman, Ph.D.
Partner

755 Page Mill Road

Palo Alto, CA 94304-1018

lsilverman@mofo.com

(650) 813-5735

BAR ADMISSIONS

California

U.S. Patent & Trademark Office

EDUCATION

Barnard College of Columbia University, B.A.

Stanford University, Ph.D.

Stanford Law School, J.D.

Dr. Lisa Silverman’s practice focuses on patent portfolio management and strategic patent counseling in the areas of life sciences, pharmaceuticals, and chemistry. She has extensive experience in securing U.S. and global patent protection for pharmaceutical products and a deep understanding of patent lifecycle management and strategies for maximizing patent term and product exclusivity. She co-leads the firm’s Pharmaceutical Patent practice, and she is a member of the firm’s Life Sciences + Healthcare Leadership Team. Lisa works with clients on diverse technologies including small molecule pharmaceuticals, antibody-drug conjugates (ADCs), peptide therapeutics, pharmaceutical formulations and uses, drug-device combinations, cosmetics, digital therapeutics, clean technology, bioassays, and medical devices.

As a member of the firm’s Venture Intellectual Property Group, Lisa routinely represents clients in both investor- and target-side IP due diligence, including patentability and freedom-to-operate assessments, and she provides advice to transactions teams on IP considerations for licensing, financing, and M&A deals. She has a keen interest in the intersection of patent and regulatory considerations for pharmaceutical products and medical devices.  She has prepared numerous applications for patent term extensions for approved drugs and medical devices, and she frequently advises on patent strategies for optimizing Orange Book listings.

Lisa represents companies of all sizes, from start-ups to multi-national corporations, as well as venture capital, private equity, and other investment firms, and she provides advice tailored to each client’s unique business needs. She has worked with large companies to ensure robust patent protection for marketed drug products. She has worked closely with mid-size companies to expand patent protection and mitigate potential infringement risks as lead drug candidates have moved through clinical development toward commercialization. She has advised small companies on securing early foundational patents.

Lisa received her J.D. from Stanford Law School. Prior to entering the legal field, Lisa obtained her Ph.D. in chemistry from Stanford University, where she was the recipient of a National Science Foundation Graduate Research Fellowship.

Experience

Clinical Stage Pharmaceutical Company

Patent counsel to clinical stage pharmaceutical company on all aspects of patent strategy and portfolio development for small molecule pipeline, including advising on IP due diligence for strategic funding collaborations and licensing agreements worth over $500 million.

Aurinia Pharmaceuticals 

Patent counsel to Aurinia Pharmaceuticals for LUPKYNIS®, the first FDA-approved oral treatment specifically for lupus nephritis.

Seagen

Patent counsel to Seagen on global portfolio for antibody-drug conjugate (ADC) pipeline candidates, platform technologies, and marketed therapeutics.

UCB

Patent counsel to UCB, a global biopharmaceutical company, on clinical-stage program for treatment of Parkinson’s disease.

Frontier Medicines

Patent counsel to Frontier Medicines, a clinical stage precision medicine company advancing treatments for genetically-defined patient populations in oncology and immunology, on all aspects of patent strategy and portfolio development for pipeline of small molecule therapeutics.

Cerus 

Patent counsel to Cerus on patent portfolio development for their pathogen-protected blood components, including the INTERCEPT® Blood System.

General Catalyst 

Advised General Catalyst on IP due diligence for various transactions, including investment in $72 million Series A funding round of Maxion Therapeutics, developer of drugs for ion channel- and G protein coupled receptor (GPCR)-driven diseases, and $155 million Series B funding round of ArriVent Biopharma, developer of pharmaceutical products intended to cure presently untreatable cancer.

Frazier Life Sciences

Advised Frazier Life Sciences in IP due diligence for launch of Callio Therapeutics, which included $187 million in series A funds for development of dual-payload antibody-drug conjugates (ADCs) for treatment of cancer.

Abingworth 

Advised Abingworth on IP due diligence for $150 million strategic development funding agreement with Teva for development of dual-action asthma rescue inhaler respiratory program.

Rankings

Recommended for Healthcare: Life Sciences

The Legal 500 US 2023